ClearLED and PEAK3 Partner to Integrate ATSC 3.0 Technology in Transparent LED Displays
NextGen TV technology promises to cut costs and boost reliability for digital signage networks without internet dependency
LAS VEGAS, March 17, 2025 /PRNewswire/ -- ClearLED, a North American leader in transparent LED display technology, and PEAK3, an ATSC 3.0-data enabled edge pathway service provider, announced a strategic partnership Monday to bring next-generation broadcast technology to digital signage solutions.
The collaboration will integrate PEAK3's ATSC 3.0 data delivery technology into ClearLED's transparent display products, potentially reducing costs and improving reliability for businesses deploying digital signage networks.
ATSC 3.0, also known as NextGen TV, delivers 4K UHD video and interactive content via over-the-air broadcast rather than internet streaming, eliminating dependency on constant internet connectivity.
"With ATSC 3.0, digital signage can harness the power of broadcast technology to deliver crystal-clear video, emergency alerts, and targeted messaging without relying on expensive data networks," said Alp Sezen, CEO at PEAK3. "This is a game-changer for businesses and municipalities looking for scalable, cost-efficient signage solutions."
The partnership comes as the U.S. digital signage market is projected to grow from $9.16 billion in 2025 to $13.38 billion by 2030, according to industry forecasts.
ClearLED's product line includes transparent LED walls, films, meshes, nets, and glass solutions for both indoor and outdoor applications. The company holds more than 20 patents on its transparent display technology.
"We at ClearLED are technology driven...period," said David Morris, CTO of ClearLED. "We provide state of the art experiences for our customers all over the world. New, novel technology, that has the ability to scale and support that value, is something we always explore."
The ATSC 3.0 integration offers several advantages for digital signage networks, including reduced reliance on internet streaming, enhanced content quality with 4K video capability, increased signal reliability, improved scalability, and emergency alerting functionality.
Recent industry data indicates that 76% of American consumers have entered previously unvisited stores due to compelling digital signage, while 68% have made purchases influenced by digital displays.
ClearLED's displays are used by global brands including Nike, Pepsi, and Zara. The company manages all aspects of client needs from custom design to maintenance, with manufacturing based in Shenzhen, China.
PEAK3 provides standards-based, wireless IP multicast network services, offering what it calls "Data-Streaming as a Service" for organizations seeking efficient data delivery methods.
For more information, visit www.clearled.com or www.peakthree.io.
About PEAK3: PEAK3 specializes in integrating ATSC 3.0 with cloud computing and software-defined networking. The company enables enterprises to dynamically rent spectrum for efficient data distribution to edge devices, particularly benefiting industries requiring large-scale software updates. For more information, visit peakthree.io.
About ClearLED:ClearLED is a North American leader in transparent LED display technology with over 20 patents. The company provides custom LED solutions including walls, films, meshes, and glass for brands like Nike, Pepsi, and Zara. Headquartered in North America with manufacturing in Shenzhen, China, ClearLED offers end-to-end project management from design to maintenance. For more information, visit www.clearled.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/clearled-and-peak3-partner-to-integrate-atsc-3-0-technology-in-transparent-led-displays-302402571.html
SOURCE Peak3
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
New IBO Survey Reveals Major Cuts to Lab Budgets Amid NIH Grant Terminations
ARLINGTON, Va., June 10, 2025 /PRNewswire/ -- A new survey conducted by Instrument Business Outlook (IBO) has uncovered significant reductions in laboratory budgets across the U.S. academic and government research landscape, with lab product spending sharply impacted by recent NIH grant terminations. The findings, based on an exclusive IBO survey, shed light on the growing financial uncertainty facing scientific research labs in 2025. The results follow widespread disruptions in NIH funding, with more than 1,500 grants totaling $7.5 billion terminated as of May 20, according to data from Grant Watch. While the exact numbers remain fluid due to inconsistent reporting by federal agencies, the toll is undeniable: R01 research grants—a cornerstone of basic research—have been particularly hard-hit, with 322 grants worth nearly $790 million terminated. "The fallout from NIH funding changes is cascading through the research ecosystem," said Tanya Samazan, Editor-In-Chief. "Our survey shows just how deeply this uncertainty is affecting labs—from basic research to clinical trial infrastructure." Survey Highlights: Budget Cuts Across the Board Conducted by the Science Advisory Board (SAB) between mid- and late May, the survey collected 117 responses from U.S.-based labs, with 88 indicating their labs were impacted by NIH-related funding disruptions. Key findings include: 59% of labs report direct impacts from NIH-related grant or contract terminations, delays, or reductions. 47% report indirect impacts. Among affected labs, nearly 60% have reduced 2025 operating budgets by more than 10%. 51% report capital budget reductions exceeding 10%. When excluding labs that were uncertain or unaffected, the scale becomes even more dramatic: 71% of labs report operating budget cuts of over 10%. 71% report similar reductions in capital budgets. Lab Tools and Consumables Hit Hardest Every category of lab spending has been affected, according to survey data: 80% of labs have reduced their 2025 consumables budgets, making it the most impacted category. 63% have cut software/informatics budgets. 70% have reduced spending on devices under $50,000. Even high-end instrumentation (>$150,000) hasn't been spared, with 62% of labs trimming these budgets. Institutes Most Affected The survey findings align with NIH grant termination data indicating the hardest-hit institutions include: National Institute of Mental Health, with over $400 million in losses. National Institute of General Medical Sciences, which lost the highest number of grants (134). Institutes heavily reliant on lab instruments, including the National Institute of Biomedical Imaging and Bioengineering and the National Human Genome Research Institute. Medical schools and hospitals have borne a significant share of the burden, accounting for 50% of terminated grants and 55% of total terminated NIH dollars. A Shifting Landscape with No Clear Path Forward The rapidly evolving nature of NIH decisions—including ongoing terminations and reinstatements—has created a volatile funding environment. Labs are being forced to make difficult decisions with limited visibility into future funding. About Instrument Business Outlook (IBO)IBO is a leading newsletter providing market intelligence for the analytical instrument industry. Published by Strategic Directions International (SDi), a division of Science and Medicine Group, IBO offers in-depth coverage of technology, business, and market trends affecting the life sciences and lab tools sectors. View original content to download multimedia: SOURCE Instrument Business Outlook
Yahoo
31 minutes ago
- Yahoo
Novo Nordisk to present array of new portfolio data including studies with semaglutide and CagriSema, expanding evidence in obesity and diabetes care at ADA 2025
Full data of Phase 3 REDEFINE 1 and 2 trial results will provide insights on the potential of CagriSema Semaglutide real-world data complements evidence from previous cardiometabolic and kidney outcomes trials Data on pipeline candidate amycretin to underscore Novo Nordisk's scientific efforts to continued innovation in obesity PLAINSBORO, N.J., June 10, 2025 /PRNewswire/ -- Novo Nordisk today announced that new data from its industry-leading cardiometabolic portfolio will be showcased at the upcoming American Diabetes Association (ADA) 85th Scientific Sessions taking place in Chicago, June 20 – 23, 2025. A total of 29 abstracts will be presented, including trials investigating the efficacy and safety of CagriSema in people with overweight/obesity (REDEFINE 1) and those with overweight/obesity and type 2 diabetes (REDEFINE 2).1 Further, new data will complement the extensive body of cardiometabolic and kidney evidence for semaglutide in people with type 2 diabetes through analyses of the SOUL, STRIDE and FLOW trials, as well as insights from additional real-world studies in adults with obesity.2-4 "We recognize the complex interplay between cardiovascular and metabolic diseases, including type 2 diabetes and obesity, which require a personalized treatment approach," said Martin Holst Lange, Executive Vice President for Development at Novo Nordisk. "As we look to build an impactful portfolio of medicines to address patient needs, our data presented at ADA 2025 demonstrates not only how we are already delivering for a wide range of these needs with semaglutide, but that we are continuing to invest in innovation to support people living with serious chronic disease." The presentation of the CagriSema REDEFINE 1 and 2 trials are the first ever Phase 3 data presented on a GLP-1 and amylin receptor agonist combination, offering insights into the potential of this investigational medicine. Data will also be presented on pipeline candidate amycretin, demonstrating Novo Nordisk's scientific efforts to deliver innovation in cardiometabolic diseases and individualized healthcare solutions.1 On June 22nd, Novo Nordisk will also host an R&D investor event on our metabolic and cardiovascular health portfolio to cover the science and abstracts presented at the congress. The event will be accessible via a live webcast on the Novo Nordisk investor website. Full details of Novo Nordisk abstracts to be presented at ADA 2025. These data for medicines containing semaglutide, CagriSema, amycretin, insulin icodec, and IcoSema are investigational: ADA Scientific Sessions:
Yahoo
33 minutes ago
- Yahoo
Sask. to put American-made booze back on the shelves
The Saskatchewan Liquor and Gaming Authority (SLGA) is resuming the purchase and distribution of American-made alcohol. All American alcohol products will now be available for purchase through all distribution centres and private liquor distributors in the province, said David Morris, a spokesperson for the corporation, in a statement to CBC on Tuesday. "This change gives Saskatchewan people the option to choose whether they want to buy these products or consider alternatives," Morris said. The federal government's 25-per-cent tariff on U.S. alcohol remains in effect. Morris said Saskatchewan consumers are still encouraged to support Saskatchewan and Canadian products when there is an option. The change comes nearly three months after the province reversed its decision to stop selling some American-branded alcohol products made in Canada. In March, the province announced a ban on all American alcohol products. It then walked back that ban for 54 brands that, while American-owned, are produced in Canada. It said in a statement the move aligned with other provinces and that it would focus its ban on alcohol produced in America.
